← boardnext 2027-06
ARCT
Arcturus Therapeutics, Inc.distress 2/10 · well-funded / low risk$5.84-2%today-75% from 52w high
Infectious Disease 1
Lead: Cystic Fibrosis · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$211M
Runway
3.6 yrs
Shares 1y
+5%
Price & events
-23.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-5.5%
1W
-17.5%
1M
-31.1%
3M
-22.4%
6M
-62.2%
1Y
-75.3%
2Y
-81.3%
5Y
-88.1%
All
Overview
- Market Cap
- $165.99M
- Enterprise Value
- $-30.38M
- Volume
- 33.67K
- 52 Week Range
- $5.84 – $23.16
- Total Shares
- 28.42M
- Float Shares
- 26.15M
- Short %
- 29.77%
- % Held by Insiders
- 7.99%
- % Held by Institutions
- 80.45%
- RVOL
- 0.07x
- Beta
- 2.36
Pipeline stages · 2 programs
ARCT-032
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ARCT-2304, Control vaccine (licensed seasonal influenza vaccine) younger adults, Control v
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | ARCT-032 | Cystic Fibrosis, CFTR Gene Mutation | — | recruiting |
| 2026-06-01 | Phase 2 | ARCT-810 | OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD | 9 | recruiting |
| 2025-06-13 | Phase 1 | ARCT-2304, Control vaccine (licensed seasonal influenza vaccine) younger adults, Control v | Influenza, Human | 212 | completed |
Catalyst news & presentations · 4
- 2026-08-10earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 2ARCT-032 · 12-week safety and efficacy study enrolling up to 20 participants.SEC 8-K
- 2026-06-26partnershipARCT-032 · Strategic CDMO/CRO collaboration with Thermo Fisher for up to $80M in services for ARCT-032.SEC 8-K
- June 30, 2025readoutPhase 2ARCT-810 · Positive Phase 2 interim data readoutSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $21 (+253% upside) · 10 analysts
- 2026-07-02Freedom BrokerBuy
- 2026-03-18B. Riley SecuritiesNeutral → Buy
- 2026-03-05CitigroupBuy
- 2026-03-04Piper SandlerOverweight
- 2026-03-04CitigroupNeutral
- 2026-01-06CitigroupNeutral
Competitors — Cystic Fibrosis
Recent news
- 2026-07-21Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - BioSpace
- 2026-07-20Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Business Wire
- 2026-07-20Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Yahoo Finance
- 2026-07-16Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-13Understanding Momentum Shifts in (ARCT) - Stock Traders Daily
- 2026-07-11Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI
- 2026-07-10ARCT Should I Buy - Intellectia AI
- 2026-07-08Arcturus Therapeutics (ARCT) Q1 2025 earnings summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.